CClinicalTrials.gg
RecruitingNCT07667686VAL-RAS-FRUpdated Aug 26, 2026

French Validation of the Recovery Assessment Scale (RAS-FR)

An observational study in Mental Health and Psychiatric Disorders, sponsored by Etablissement Public de Santé Mentale de Metz-Jury. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Etablissement Public de Santé Mentale de Metz-Jury · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
260
Ages
18 Years and older
Sex
All
01

Study summary

The VAL-RAS-FR study aims to cross-culturally adapt, validate, and develop derived versions of the Recovery Assessment Scale (RAS), an internationally used self-report measure of subjective recovery in mental health. The study will include 260 adult psychiatric patients receiving care at EPSM Metz-Jury in both inpatient and outpatient settings. Participants will complete the French version of the RAS (RAS-FR), the WHOQOL-BREF, and additional self-report questionnaires. A subgroup of participants will complete the RAS-FR again after one month to assess test-retest reliability. The study will also explore existential aspects of recovery through the development of the RAS-FR-EX (Existential Extension) and support the development of a shorter version, the RAS-FR-SF (Short Form), for clinical and research purposes.

Read the detailed description

Recovery in mental health extends beyond symptom reduction and includes hope, self-confidence, autonomy, meaning, and continuity of self. As described by Anthony (1993) and further developed through the CHIME framework, recovery is a deeply personal process involving connectedness, hope, identity, meaning, and empowerment. Although French translations of the Recovery Assessment Scale (RAS) have been used previously, no comprehensive psychometric validation of a French version is currently available for routine use in French-speaking psychiatric settings.

VAL-RAS-FR is a monocentric, prospective, observational study designed to cross-culturally adapt, validate, and develop derived versions of the 41-item Recovery Assessment Scale (RAS) for use in French-speaking mental health settings. The study will enroll 260 adult psychiatric patients receiving care at EPSM Metz-Jury, including patients from inpatient units, day hospital settings, community mental health centers (CMP), and EPSIAD follow-up services. Participants will complete self-report questionnaires including the French version of the RAS (RAS-FR), the WHOQOL-BREF, and complementary questionnaires exploring factors associated with subjective recovery. A subgroup of 50 participants will complete the RAS-FR again after one month to assess test-retest reliability.

The study has three complementary objectives. First, it aims to evaluate the psychometric properties of the French version of the RAS, including validity, internal consistency, dimensional structure, and test-retest reliability. Second, it will explore an existential dimension of recovery through the development of the RAS-FR-EX (Existential Extension), an exploratory extension designed to assess aspects such as continuity of self, reconstruction of meaning, and the experience of existing after psychological crisis. Third, it will support the exploratory development of a shorter version of the scale, the RAS-FR-SF (Short Form), intended to facilitate future clinical use while preserving the core dimensions of subjective recovery.

The study does not involve any modification of usual care, invasive procedures, or additional medical examinations. By combining psychometric validation with exploratory clinical development, VAL-RAS-FR aims to provide a validated French-language measure of subjective recovery, improve the assessment of recovery-oriented outcomes in psychiatric care, and contribute to the development of clinically useful tools for French-speaking mental health services.

02

Conditions studied

  • Mental Health
  • Psychiatric Disorders

Keywords

  • subjective recovery
  • psychiatric care
  • psychometric validation
  • Recovery Assessment Scale
  • patient-reported outcome
  • mental health
  • RAS
  • mental health recovery
  • quality of life
  • WHOQOL-BREF
  • cross-cultural adaptation
  • recovery-oriented care
  • existential recovery
  • RAS-FR
  • French validation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult psychiatric patients receiving care at EPSM Metz-Jury in inpatient units, day hospital settings, community mental health centers (CMP), or through intensive home-based psychiatric care services (EPSIAD). Participants are French-speaking adults able to complete self-report questionnaires independently or with assistance if needed. Patients under legal protection measures may participate in accordance with applicable regulations.

Inclusion criteria

  • Adult patient (18 years or older)
  • Receiving psychiatric care at EPSM Metz-Jury (inpatient unit, day hospital, community mental health center [CMP], or intensive home-based psychiatric care service [EPSIAD]/post-EPSIAD follow-up)
  • Able to understand French
  • Able to complete a self-report questionnaire independently or with assistance if needed
  • Patients under legal protection measures (guardianship or curatorship) may participate with the agreement of their legal representative, when applicable

Exclusion criteria

Exclusion Criteria:

  • Major cognitive impairment
  • Severe clinical condition preventing questionnaire completion or understanding of French
  • Refusal to participate
  • Prisoner or person deprived of liberty by judicial or administrative decision
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
260 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult psychiatric patients

    Adult psychiatric patients receiving care at EPSM Metz-Jury (inpatient units, day hospital, community mental health centers \[CMP\], and intensive home-based psychiatric care services \[EPSIAD\]) who are able to complete self-report questionnaires in French.

    Other: Self-report questionnaires

Interventions

  • OtherSelf-report questionnaires

    Participants complete self-report questionnaires including the French version of the Recovery Assessment Scale (RAS-FR), the WHOQOL-BREF, and complementary questionnaires related to subjective recovery. The study also includes the exploratory assessment of six additional existential items. A subgroup of 50 participants will complete the RAS-FR again after one month to assess test-retest reliability. No therapeutic intervention, modification of usual care, invasive procedure, or additional medical examination is involved.

05

What researchers measure

Primary outcomes

  1. Recovery Assessment Scale - French Version (RAS-FR): Total Score, Internal Consistency, Factor Structure, and Test-Retest Reliability

    The Recovery Assessment Scale - French Version (RAS-FR) is a 41-item self-report questionnaire assessing subjective recovery in mental health. Total scores range from 41 to 205, with higher scores indicating a higher level of subjective recovery. Psychometric analyses will include internal consistency, dimensional structure, and test-retest reliability.

    Time frame: Baseline and 1 month

Secondary outcomes

  1. Correlation between Recovery Assessment Scale - French Version (RAS-FR) and WHOQOL-BREF (World Health Organization Quality of Life - Brief Version) scores

    Assessment of convergent validity through correlations between the Recovery Assessment Scale - French Version (RAS-FR) total score and WHOQOL-BREF domain scores in adult psychiatric patients, with particular attention to the psychological and social relationship domains. The RAS-FR total score ranges from 41 to 205, with higher scores indicating a higher level of subjective recovery. WHOQOL-BREF domain scores range from 0 to 100, with higher scores indicating better perceived quality of life. Pearson or Spearman correlation coefficients will be calculated.

    Time frame: Baseline

  2. Existential dimension of recovery (RAS-FR-EX) composite score

    Exploratory assessment of the existential dimension of recovery using six additional items integrated into the French version of the Recovery Assessment Scale (RAS-FR-EX). A composite score ranging from 6 to 30 will be calculated, with higher scores indicating a stronger endorsement of existential recovery processes.

    Time frame: Baseline

  3. Development of a short-form Recovery Assessment Scale - French Version (RAS-FR-SF)

    Exploratory item reduction analyses based on responses to the 41-item Recovery Assessment Scale - French Version (RAS-FR). The objective is to identify a shorter version of the instrument while preserving its psychometric properties and conceptual coverage of subjective recovery.

    Time frame: Baseline

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be made publicly available. Access to study data may be considered on a case-by-case basis upon request to the sponsor, subject to regulatory requirements, confidentiality obligations, and GDPR compliance.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07667686
Lead sponsor
Etablissement Public de Santé Mentale de Metz-Jury
Collaborators
Centre Hospitalier Régional Metz-Thionville, Groupement Interrégional de Recherche Clinique et d'Innovation
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jun 29, 2026
Primary completion
Jan 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 26, 2026

Study contacts

Audrey WILLIG, Psychologist
Contact
audrey.willig@gmail.com
+33695082545
Claire GARIOT, PhD
Contact
claire.gariot@epsm-metz-jury.fr
+33387561234
Audrey WILLIG, Psychologist
principal investigator · Clinical Research Unit (URC), EPSM Metz-Jury

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion